Please assess the completion status of the following clinical trial:

Trial Title: PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age between 24 weeks and 27 weeks + 6 days~* Babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (PPROM), or preterm labor~* Written informed consent obtained before inclusion and randomization.~Exclusion Criteria:~* Babies born to mothers with birth weight below the 3th percentile~* PPROM before 22 weeks~* Major fetal anomaly or congenital malformation~* Mother refusal or inability to provide consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- 1: hydrocortisone (Type: EXPERIMENTAL): 1: active arm treated with low doses of HC during the first 10 days of life
- 2: Placebo (Type: PLACEBO_COMPARATOR): 2:placebo arm treated with placebo at the same conditions than active arm

Based on this trial design, predict the completion outcome and termination type (if applicable).